Genetically engineered, attenuated whole-cell vaccine approaches for malaria

Human Vaccines

Volumn 6, Issue 1, 2010, Pages

  Vaughan, Ashley M ^a   Wang, Ruobing ^a,b   Kappe, Stefan H I ^a,b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Attenuation; Elimination; Liver stage; Malaria; Mosquito; Plasmodium; Pre erythrocytic stages; Sporozoite; Vaccine

Indexed keywords

CHLOROQUINE; CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; PRIMAQUINE; RTS S VACCINE; SPOROZOITE VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE;

DRUG EFFICACY; GENE DELETION; GENE EXPRESSION; GENETIC ENGINEERING; HEPATITIS; HUMAN; IMMUNIZATION; MALARIA; NONHUMAN; PARASITE IDENTIFICATION; PLASMODIUM FALCIPARUM; REVIEW; VACCINE PRODUCTION; GENETICS; IMMUNOLOGY; MALARIA FALCIPARUM; SPOROZOITE;

HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; SPOROZOITES; VACCINES, ATTENUATED;

EID: 74949087025     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.1.9654     Document Type: Review

References (75)

1. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008; 5:38.
2. Greenwood BM. Control to elimination: implications for malaria research. Trends Parasitol 2008; 24:449-54.
3. Vanderberg JP, Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol 2004; 34:991-6.
4. Amino R, Thiberge S, Martin B, Celli S, Shorte S, Frischknecht F, et al. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat Med 2006; 12:220-4.
5. Frevert U, Engelmann S, Zougbede S, Stange J, Ng B, Matuschewski K, et al. Intravital observation of Plasmodium berghei sporozoite infection of the liver. PLoS Biol 2005; 3:192.
6. Mueller AK, Camargo N, Kaiser K, Andorfer C, Frevert U, Matuschewski K, et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 2005; 102:3022-7.
7. Charoenvit Y, Mellouk S, Sedegah M, Toyoshima T, Leef MF, De la Vega P, et al. Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody. Exp Parasitol 1995; 80:419-29.
8. Singh AP, Buscaglia CA, Wang Q, Levay A, Nussenzweig DR, Walker JR, et al. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 2007; 131:492-504.
9. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature 2002; 415:673-9.
10. Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984; 225:593-9.
11. Enea V, Ellis J, Zavala F, Arnot DE, Asavanich A, Masuda A, et al. DNA cloning of Plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope. Science 1984; 225:628-30.
12. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997; 336:86-91.
13. Alonso PL. Malaria: deploying a candidate vaccine (RTS,S/AS02A) for an old scourge of humankind. Int Microbiol 2006; 9:83-93.
14. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, et al. Duration of protection with RTS,S/ AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: singleblind extended follow-up of a randomised controlled trial. Lancet 2005; 366:2012-8.
15. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364:1411-20.
16. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521-32.
17. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007; 370:1543-51.
18. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967; 216:160-2.
19. Nussenzweig RS, Vanderberg J, Spitalny GL, Rivera CI, Orton C, Most H. Sporozoite-induced immunity in mammalian malaria. A review. Am J Trop Med Hyg 1972; 21:722-8.
20. Alger NE, Harant J. Plasmodium berghei: heat-treated sporozoite vaccination of mice. Exp Parasitol 1976; 40:261-8.
21. Doolan DL, Martinez-Alier N. Immune response to pre-erythrocytic stages of malaria parasites. Curr Mol Med 2006; 6:169-85.
22. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973; 266:169-77.
23. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1974; 68:258-9.
24. Vanbuskirk KM, O'Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA 2009; 106:13004-9.
25. Vanderberg JP, Nussenzweig RS, Most H, Orton CG. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei II. Effects of radiation on sporozoites. J Parasitol 1968; 54:1175-80.
26. Tsuji M, Zavala F. T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol 2003; 19:88-93.
27. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185:1155-64.
28. Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003; 206:3803-8.
29. Wong KA, Zhou A, Rodriguez A. Protective immunity induced by daily bites from irradiated mosquitoes infected with Plasmodium yoelii. Parasite Immunol 2008; 30:482-6.
30. Chattopadhyay R, Conteh S, Li M, James ER, Epstein JE, Hoffman SL. The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine. Vaccine 2009; 27:3675-80.
31. Sedegah M, Weiss WW, Hoffman SL. Crossprotection between attenuated Plasmodium berghei and P. yoelii sporozoites. Parasite Immunol 2007; 29:559-65.
32. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 2008; 455:757-63.
33. Carlton JM, Angiuoli SV, Suh BB, Kooij TW, Pertea M, Silva JC, et al. Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 2002; 419:512-9.
34. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419:498-511.
35. Mikolajczak SA, Silva-Rivera H, Peng X, Tarun AS, Camargo N, Jacobs-Lorena V, et al. Distinct malaria parasite sporozoites reveal transcriptional changes that cause differential tissue infection competence in the mosquito vector and mammalian host. Mol Cell Biol 2008; 28:6196-207.
36. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005; 433:164-7.
37. + T Cells. J Infect Dis 2007; 196:608-16.
38. Mikolajczak SA, Jacobs-Lorena V, MacKellar DC, Camargo N, Kappe SH. L-FABP is a critical host factor for successful malaria liver stage development. Int J Parasitol 2007; 37:483-9.
39. van Dijk MR, Douradinha B, Franke-Fayard B, Heussler V, van Dooren MW, van Schaijk B, et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 2005; 102:12194-9.
40. Ishino T, Chinzei Y, Yuda M. Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte. Mol Microbiol 2005; 58:1264-75.
41. Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 2007; 75:3758-68.
42. Kumar KA, Baxter P, Tarun AS, Kappe SH, Nussenzweig V. Conserved protective mechanisms in radiation and genetically attenuated uis3(-) and uis4(-) Plasmodium sporozoites. PLoS ONE 2009; 4:4480.
43. + T Cells. J Infect Dis 2007; 196:599-607.
44. Mueller AK, Deckert M, Heiss K, Goetz K, Matuschewski K, Schluter D. Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. Am J Pathol 2007; 171:107-15.
45. Aly AS, Mikolajczak SA, Rivera HS, Camargo N, Jacobs-Lorena V, Labaied M, et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol 2008; 69:152-63.
46. Tarun AS, Peng X, Dumpit RF, Ogata Y, Silva-Rivera H, Camargo N, et al. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci USA 2008; 105:305-10.
47. Yu M, Kumar TR, Nkrumah LJ, Coppi A, Retzlaff S, Li CD, et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 2008; 4:567-78.
48. Vaughan AM, O'Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 2009; 11:506-20.
49. Douradinha B, van Dijk MR, Ataide R, van Gemert GJ, Thompson J, Franetich JF, et al. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. Int J Parasitol 2007; 37:1511-9.
50. van Schaijk BC, Janse CJ, van Gemert GJ, van Dijk MR, Gego A, Franetich JF, et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS ONE 2008; 3:3549.
51. Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, Leroy N, et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004; 172:2487-95.
52. Putrianti ED, Silvie O, Kordes M, Borrmann S, Matuschewski K. Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. J Infect Dis 2009; 199:899-903.
53. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009; 361:468-77.
54. Ocana-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med 2003; 197:143-51.
55. + T cells during the course of blood-stage malarial infection. J Infect Dis 2007; 196:1827-35.
56. Jin Y, Kebaier C, Vanderberg J. Direct microscopic quantification of dynamics of Plasmodium berghei sporozoite transmission from mosquitoes to mice. Infect Immun 2007; 75:5532-9.
57. Waters AP, Mota MM, van Dijk MR, Janse CJ. Parasitology. Malaria vaccines: back to the future? Science 2005; 307:528-30.
58. Good MF. Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. Trends Immunol 2005; 26:295-7.
59. Overstreet MG, Cockburn IA, Chen YC, Zavala F. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol Rev 2008; 225:272-83.
60. + T-cell responses against malaria liver stages. Nat Med 2002; 8:166-70.
61. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 1988; 85:573-6.
62. + T lymphocytes is required for protective immunity against Plasmodium berghei. J Immunol 1996; 156:3374-81.
63. Wizel B, Houghten RA, Parker KC, Coligan JE, Church P, Gordon DM, et al. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med 1995; 182:1435-45.
64. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol 2000; 165:1453-62.
65. Klotz FW, Scheller LF, Seguin MC, Kumar N, Marletta MA, Green SJ, et al. Co-localization of inducible-nitric oxide synthase and Plasmodium berghei in hepatocytes from rats immunized with irradiated sporozoites. J Immunol 1995; 154:3391-5.
66. Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol 1987; 139:2020-5.
67. + T cells. J Exp Med 1994; 180:353-8.
68. + T cell-mediated protective antimalaria immunity elicited by recombinant adenovirus. Parasite Immunol 2000; 22:157-60.
69. + T lymphocytes against liver stages of Plasmodium yoelii do not require gamma interferon for antiparasite activity. Infect Immun 2008; 76:3628-31.
70. + T lymphocytes protective against malaria liver stages are primed in skindraining lymph nodes. Nat Med 2007; 13:1035-41.
71. +T cells against liver-stage malaria. PLoS ONE 2009; 4:5075.
72. Plebanski M, Hannan CM, Behboudi S, Flanagan KL, Apostolopoulos V, Sinden RE, et al. Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses. Immunol Cell Biol 2005; 83:307-12.
73. Scheller LF, Azad AF. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci USA 1995; 92:4066-8.
74. + T cells. J Immunol 2003; 171:2024-34.
75. Di Giulio G, Lynen G, Morzaria S, Oura C, Bishop R. Live immunization against East Coast fever-current status. Trends Parasitol 2009; 25:85-92.